Wei Wu
Corporate Officer/Principal chez Johnson & Johnson Innovation - JJDC, Inc.
Profil
Wei Wu is currently a Principal at Johnson & Johnson Innovation - JJDC, Inc. Prior to this, he worked as a Senior Associate at IIF Management Co. LLC from 2019 to 2021.
He also served as a Board Member at Immpact Bio USA, Inc. from 2021 to 2022 and as an Advisory Board Member at Cura Therapeutics from 2019 to 2020.
Mr. Wu received his undergraduate degree from Peking University and his doctorate degree from the University of California.
Postes actifs de Wei Wu
| Sociétés | Poste | Début |
|---|---|---|
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Corporate Officer/Principal | 01/02/2021 |
Anciens postes connus de Wei Wu
| Sociétés | Poste | Fin |
|---|---|---|
Immpact Bio USA, Inc.
 Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | Directeur/Membre du Conseil | 01/01/2022 |
IIF Management Co. LLC
 IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Analyste en capital-investissement | 01/01/2021 |
Cura Therapeutics
 Cura Therapeutics Pharmaceuticals: MajorHealth Technology Cura Therapeutics is a Canadian company that is developing innovative immunotherapies to cure cancer and infectious diseases. The company is based in Québec, Canada. The company is developing a first-in-class multifunctional immunotherapy platform that harnesses cytokines and immune receptors to create multifunctional proteins with potent anti-cancer and anti-viral properties. The company's lead immunotherapy, CT101, is a multifunctional cytokine fusion protein that activates and synchronizes several immune system mechanisms to destroy cancer cells. Cura Therapeutics was founded by Collin Horner, Claudia A. Penafuerte Diaz, and Claudia A. Penafuerte Diaz has been the CEO since incorporation. | Consultant / Advisor | 01/01/2020 |
Formation de Wei Wu
| Peking University | Undergraduate Degree |
| University of California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
IIF Management Co. LLC
IIF Management Co. LLC Investment ManagersFinance IIF Management Co LLC (Illumina Ventures) is a venture capital firm founded in 2015 by Nicholas J. Naclerio. The firm is headquartered in Foster City, California. | Finance |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
Immpact Bio USA, Inc.
Immpact Bio USA, Inc. BiotechnologyHealth Technology ImmPACT Bio USA, Inc. operates as a cell therapy company. The firm develops potent and selective engineered T-cells for the treatment of solid tumors. The company is headquartered in Camarillo, CA. | Health Technology |
Cura Therapeutics
Cura Therapeutics Pharmaceuticals: MajorHealth Technology Cura Therapeutics is a Canadian company that is developing innovative immunotherapies to cure cancer and infectious diseases. The company is based in Québec, Canada. The company is developing a first-in-class multifunctional immunotherapy platform that harnesses cytokines and immune receptors to create multifunctional proteins with potent anti-cancer and anti-viral properties. The company's lead immunotherapy, CT101, is a multifunctional cytokine fusion protein that activates and synchronizes several immune system mechanisms to destroy cancer cells. Cura Therapeutics was founded by Collin Horner, Claudia A. Penafuerte Diaz, and Claudia A. Penafuerte Diaz has been the CEO since incorporation. | Health Technology |